Sterling
Sterling Pharma Solutions is a global contract development and manufacturing organisation (CDMO), specialising in complex and hazardous science. Our dedicated bioconjugation and ADC facility in the UK supports customer’s projects from development to preclinical and clinical manufacture.
This specialised team is supported by high potency small molecule experts at our Wisconsin, US site providing integrated ADC services, including toxin linker manufacturing.
Sterling has six facilities across the UK, USA and Europe, employing more than 1,350 people.
